AuraSonics holds a layered patent portfolio over a category-defining architecture in cardiac sensing: a high-density, dual-energy, AI-readable thoracic signal platform. We are raising a seed round to convert it — five filings, three families — into granted utility patents and a first working prototype — and the first dollar doesn't disappear into burn. It goes straight to one of the world's top life-sciences law firms.
We are defining a new category — Wearable Cardiac Tomography. This is the entry point: the moment before the category is priced in, when early conviction is rewarded with the simplest terms it will ever have.
Cardiovascular disease is the world's leading cause of death — yet definitive diagnosis is still episodic, expensive, and triggered only after symptoms. Capital is flowing into AI-enabled, non-invasive sensing — and the best-funded names are chasing a far narrower signal than ours.
And this moat compounds. A single-point device can record a million patients and never hold what a coordinate-aligned field captures in one session. The competitor who starts five years late starts five years of irreplaceable data behind — a lead that capital alone cannot buy back.
The world's leading cause of death — an estimated 19.8 million in 2022 — still found too late.
Eko raised $150M+ to connect one acoustic sensor to AI. The field is funded, the incumbents narrow — and a sensor that rides the chest cannot feel motion.
Medtech venture funding rebounded through 2025 and AI-enabled healthtech is in strong demand — an ideal backdrop for a seed.
Independent analysts size the market in the low-to-mid tens of billions — and care is shifting from episodic testing toward exactly what AuraSonics builds.
Multiple analyst groups value the market in the low-to-mid tens of billions, growing high-single-digit annually.
Past $25B by the mid-2030s — pulled by AI, wearables, and remote monitoring, the exact tailwinds we ride.
No competitor captures both energies across a 3,000-point, coordinate-aligned field. The category is, so far, our own.
Market figures are third-party analyst estimates, cited as a range and rounded; they describe the opportunity, not a projection of AuraSonics revenue.
Most pre-seed money funds runway and hope. Ours funds a specific, verifiable asset: an interlocking patent estate — five filings across three families — protecting the fourteen capabilities that define the platform. An angel's contribution can be ring-fenced and paid directly to Wilson Sonsini to convert the four provisionals into utility applications — the single step that most increases this company's value.
Angel / advisor contribution
Not to burn. Not to salaries. Earmarked for the IP.
Provisional → utility, by top counsel
Wilson Sonsini has supported AuraSonics' formation and IP foundation, giving investors a clean corporate and legal starting point.
Founder-backed to date, company-owned IP, and a clean early-stage structure. You enter early, on simple terms.
Utility filings authored by world-renowned counsel carry weight that opens the doors a founder cannot open alone.
The instrument is open to discussion — SAFE or priced. The entry point is yours to choose.
A focused, earmarked contribution paid directly to counsel to file the utility patents. The cleanest possible first step into the company.
The full round to carry AuraSonics from protected IP to a working belt and first human feasibility data — on the path toward an FDA regulatory strategy.
IP first — because the patent conversion is the highest-leverage, lowest-risk value creation available to this company today.
Allocation is representative and will be finalized with lead investors. Fabrication partners in Malaysia and South Korea are already identified.
Provisional → utility conversion completed by Wilson Sonsini — the company's core IP risk retired.
First working belt built to existing specifications, with bench signal validation — the physics demonstrated before any clinical claim.
Initial feasibility recordings and a physician-facing dashboard mockup.
Regulatory pathway memo, pilot-site letters of intent, and an initial dataset for model development.
We believe in showing the team honestly. The technical foundation is in place; this round funds the credibility and the advisors that come next.
Architect of the AuraSonics dual-energy sensing platform — five filings across three patent families, every one assigned to the company. He leads the technical vision and personally answers investor inquiries.
The bench this round is designed to fund: cardiology, FDA regulatory pathway, signal processing, wearable-sensor engineering, and AI/ML medical-device leadership.
In formationCompany-owned patent portfolio covering high-density mechano-acoustic cardiac sensing — fourteen defensible capabilities, clean structure, unencumbered IP.
One of the world's leading technology and life-sciences law firms. Engaged on formation and IP; available to speak with serious prospective investors about the patent portfolio.
No spin. The honest version of every answer — because the diligence will find it anyway.
The conversion of the provisional portfolio into utility patent applications, the first working sensing belt, and initial bench validation. The entry tranche can be ring-fenced and paid directly to Wilson Sonsini — your dollar becomes a defensible asset, not runway.
The "smart stethoscope" field digitizes a single acoustic point. AuraSonics captures two physically different energies across 3,000 coordinate-aligned points — and a sensor that rides the chest cannot feel motion. A different sense, not a better microphone.
No — and we say so plainly. AuraSonics is development-stage; figures such as >70 dB SNR and 1–3 mm localization are engineering and modeled targets, not clinical results. This round funds the first steps toward validating them. Honest framing today is what survives diligence tomorrow.
An interlocking estate — sensing hardware, signal pipeline, data-fusion engine — five filings across three families, covering the platform's fourteen defensible capabilities. One utility application is already filed; four provisionals now enter conversion. Plus a compounding data moat: a coordinate-aligned field cannot be reconstructed by a rival who starts late.
Intentionally simple — SAFE or priced. Begin with the ring-fenced patent tranche, or back the full $1.0–1.5M seed; speak with our counsel before committing a dollar.
Capital is flowing into AI-enabled, non-invasive cardiac sensing; the market is scaling past $25B; and the category is still unpriced. This is the entry point — when early conviction is rewarded with the simplest terms it will ever have.
This page is for informational purposes only and does not constitute an offer to sell, or the solicitation of an offer to buy, any security. Any such offer will be made only to qualified investors pursuant to definitive offering documents. Statements about future plans, milestones, and markets are forward-looking and subject to risk and uncertainty. AuraSonics, Inc. is a development-stage company; its technology is the subject of pending provisional patent applications, has not been clinically validated, and is not FDA-cleared. Performance figures referenced elsewhere on this site are engineering or modeled targets.